THE FIRST biomarker assay for pediatric acute kidney injury risk assessment
BioPorto welcomes ProNephro AKI (NGAL) to its family of NGAL products in the race against acute kidney injury.
Commercial availability in the US is expected in 2024.
NGAL for clinical use
In conjunction with clinical evaluation, our particle-enhanced turbidimetric immunoassays are designed to assess the risk of acute kidney injury (AKI) in critically ill patients as quickly as 2 hours after the initial insult.
The NGAL TestTM
CE-Marked since 2011 in the EU, The NGAL Test* provides a quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine and plasma.
*The NGAL Test is CE marked and available for in vitro diagnostic use in the EU, Canada, and Korea. For research use only in all other regions.READ MORE
ProNephro AKITM (NGAL)
FDA-cleared for use in the US in 2023, ProNephro AKI* is intended to be used in the first 24 hours of ICU admission as an aid to identify pediatric patients (≥3 months to <22 years) at risk of developing or having persistent moderate to severe acute kidney injury in the next 48 to 72 hours.
*ProNephro AKI is FDA-cleared. US commercial availability expected in 2024.READ MORE
NGAL for research
BioPorto has a unique range of human and animal NGAL antibodies and ELISA kits for your research projects.
BioPorto offers a range of leading, highly reproducible ELISA kits that are easy to use, including the CE marked human ELISA Kit for nephrotoxicity.READ MORE
BioPorto offers high-quality monoclonal antibodies for pharmaceutical research and IVD testing in areas such as diabetes, obesity, and allergy.
Bulk antibodies are available in custom volumes.READ MORE